Case Report

Severe acute encephalopathy related to human parainfluenza virus type 2 infection in an infant: a case report

Kazuko Sugai,1 Hiroyuki Tsukagoshi,2 Ikuko Nojima,1 Kaori Fujiwara,1 Aya Kodera,1 Noriko Kimura,3 Keiji Tsuchimoto,1 Kazuhiro Sekimoto,1 Kumimi Kitada,1 Nobumasa Takahashi,1 Tooru Araki,1 Yosuke Fujii,4 Yumiko Miyaji,5 Masanori Ikeda,1,4 Kunihisa Kozawa,2 Masahiro Noda,6 Makoto Kuroda7 and Hirokazu Kimura6

Correspondence
Kazuko Sugai
kazgoto@be.mbn.or.jp

1Department of Pediatrics, National Hospital Organization Fukuyama Medical Center, 4-14-17 Okinogami-cho, Fukuyama, Hiroshima 720-8520, Japan
2Gunma Prefectural Institute of Public Health and Environmental Sciences, 378 Kamioki-cho, Maebashi, Gunma 371-0052, Japan
3Department of Pediatrics, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences, 2-5-1 Shikada-cho, Okayama 700-8558, Japan
4Department of Pediatric Acute Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikada-cho, Okayama 700-8558, Japan
5National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan
6National Institute of Infectious Disease, Infectious Disease Surveillance Center, 4-7-1, Gakuen, Musashimurayama, Tokyo 208-0011, Japan
7Pathogen Genomics Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan

Introduction: We present here a rare case of severe acute encephalopathy with extra-pulmonary symptoms in a two-year-old girl caused by human parainfluenza virus type 2 (HPIV2) infection.

Case Presentation: The patient was brought in by ambulance, presenting with fever, hypoxia and generalized tonic-clonic seizure, and was admitted into Fukuyama Medical Center. She had a depressed level of consciousness with drowsiness. Her Glasgow coma score was 6. Based on the results of laboratory examinations, brain computed tomography, brain magnetic resonance imaging and electroencephalography, we diagnosed her with acute encephalopathy. Treatment was initiated with high-dose intravenous immunoglobulin, methylprednisolone pulse therapy and edaravone along with mechanical ventilation. We confirmed HPIV2 infection using samples of sputum from the intra-tracheal tube, throat swab and blood using next-generation sequencing and the PCR method. After continued steroid and anti-inflammatory therapy, the patient recovered completely.

Conclusion: Extra-pulmonary symptoms in parainfluenza viral infections are rare. HPIV2 infection can cause severe acute encephalopathy via a systemic immunological reaction along with airway symptoms.

Keywords: acute encephalopathy; edaravone; human parainfluenza virus type 2 infection/seizure; intravenous immunoglobulin; intravenous steroids.

Received 15 May 2015
Accepted 15 June 2015

Abbreviations: AST, aspartate aminotransferase; CMV, cytomegalovirus; CSF, cerebrospinal fluid; CT, computed tomography; EBV, Epstein–Barr virus; EEG, electroencephalography; HHV, human herpesvirus; HN, haemagglutinin-neuraminidase; HPIV2, human parainfluenza virus type 2; HSV, herpes simplex virus; IVIG, intravenous immunoglobulin; LDH, lactate dehydrogenase; MRI, magnetic resonance imaging; NGS, next-generation sequencing; RSV, respiratory syncytial virus; VZV, varicella-zoster virus.

The GenBank/EMBL/DDBJ accession number of the haemagglutinin-neuraminidase coding region sequence obtained in this study is LC050829.
**Introduction**

Human parainfluenza viruses (HPIVs) are respiratory viruses that commonly cause respiratory infections in children (Henrickson, 2003). In recent years, the importance of extra-pulmonary symptoms of HPIV infection has become evident, and severe cases of HPIV-related encephalitis have been reported (Kim & You, 2012; Abenhaim Halpern et al., 2013).

Here, we report a case of a two-year-old girl who was diagnosed with HPIV-induced acute encephalitis, presenting with fever, seizure and reduced level of consciousness. HPIV2 was detected using next-generation sequencing (NGS), and other viruses that typically cause encephalopathy, such as the Epstein–Barr virus (EBV), cytomegalovirus (CMV), herpes simplex virus (HSV), varicella-zoster virus (VZV), human herpesvirus (HHV)6 and HHV7, were not detected.

**Case report**

A two-year-old girl was brought to our hospital by ambulance with fever, hypoxia and generalized tonic-clonic seizure. She had a mild nasal discharge and cough for half a day before admission. She had a history of severe neonatal asphyxia and an Apgar score of 2/8 and had been delivered at the gestational age of 32 weeks. However, routine follow-up revealed good development, with normal findings on brain magnetic resonance imaging (MRI) and electroencephalography (EEG).

At the time of hospital admission, the patient also had laryngomalacia, for which tracheotomy was performed. Her Glasgow coma score was 6. The seizure resolved with anticonvulsant treatment, but the consciousness level did not improve. Essential laboratory data are shown in Table 1. Serum levels of aspartate aminotransferase (AST; 99 IU l⁻¹), lactate dehydrogenase (LDH; 466 IU l⁻¹), ferritin (143.3 ng ml⁻¹) and amyloid A (153.3 µg ml⁻¹) were elevated; therefore, we considered that she had severe systemic inflammation. The cerebrospinal fluid (CSF) was sampled on the day of admission, and the cell count was 1 cell µl⁻¹. Rapid diagnostic tests using nasal or throat swabs for respiratory syncytial virus (RSV), influenza virus, adenovirus, and human metapneumovirus were all negative. Immediately after hospitalization, although brain MRI did not suggest inflammation (Fig. 1a), brain computed tomography (CT) showed brain oedema. Based on these findings, as well as considering the persisting depressed level of consciousness, we diagnosed severe acute encephalopathy. Prior to starting treatment, we obtained the guardian’s informed consent for obtaining a nasal swab, intra-tracheal sputum sample and blood samples on the day of admission. Therapy was initiated with 0.5 g d-mannitol kg⁻¹ per dose four times per day for reducing cerebral oedema and 0.12 mg midazolam kg⁻¹ h⁻¹ continuously for preventing seizure. Further, 1 g high-dose intravenous immunoglobulin (IVIG) kg⁻¹ day⁻¹, 30 mg methylprednisolone pulse therapy kg⁻¹ day⁻¹ for 3 days, 500 U thrombomodulin alfa day⁻¹, and 0.5 g edaravone kg⁻¹ dose⁻¹ twice a day were concomitantly administered, similar to the therapy for influenza-virus-associated encephalopathy. Mechanical ventilation was started for the respiratory symptoms. Further, we administered 150 mg cefotaxime kg⁻¹ day⁻¹ since the white blood cell count and C-reactive protein levels were elevated. However, bacterial cultures for blood and CSF were negative, and throat swab culture detected normal flora.

After the initiation of treatment, the patient’s consciousness improved briefly; however, on day 4 of admission, her consciousness worsened and the laboratory data suggested severe systemic inflammation. MRI on day 6 showed high-signal areas in the anterior lobes; therefore, we restarted methylprednisolone pulse therapy and increased the d-mannitol dose (Fig. 1b). Subsequently,

---

**Table 1. Clinical laboratory data from the acute and convalescent phases**

<table>
<thead>
<tr>
<th>Item</th>
<th>Acute phase (day 1, admission)</th>
<th>Acute phase (day 2)</th>
<th>Convalescent phase (day 28)</th>
</tr>
</thead>
<tbody>
<tr>
<td>White blood cell (mm⁻³)</td>
<td>16 400</td>
<td>14 900</td>
<td>8000</td>
</tr>
<tr>
<td>Neutrophils (%)</td>
<td>19.0</td>
<td>67.0</td>
<td>72.0</td>
</tr>
<tr>
<td>Platelet count (mm⁻³)</td>
<td>21.1 × 10⁴</td>
<td>18.0 × 10⁴</td>
<td>33.9 × 10⁴</td>
</tr>
<tr>
<td>Fibrin degradation products (µg dl⁻¹)</td>
<td>5.5</td>
<td>7.1</td>
<td>1.4</td>
</tr>
<tr>
<td>D-Dimer (µg ml⁻¹)</td>
<td>2.1</td>
<td>2.4</td>
<td>0.2</td>
</tr>
<tr>
<td>Total protein (g dl⁻¹)</td>
<td>7.2</td>
<td>7.9</td>
<td>7.9</td>
</tr>
<tr>
<td>Albumin (g dl⁻¹)</td>
<td>4.3</td>
<td>3.4</td>
<td>3.9</td>
</tr>
<tr>
<td>Aspartate aminotransferase (IU l⁻¹)</td>
<td>99</td>
<td>81</td>
<td>73</td>
</tr>
<tr>
<td>Alanine aminotransferase (IU l⁻¹)</td>
<td>35</td>
<td>36</td>
<td>27</td>
</tr>
<tr>
<td>Lactate dehydrogenase (IU l⁻¹)</td>
<td>466</td>
<td>422</td>
<td>496</td>
</tr>
<tr>
<td>C-reactive protein (mg dl⁻¹)</td>
<td>4.8</td>
<td>30.4</td>
<td>0.9</td>
</tr>
<tr>
<td>Ferritin (ng ml⁻¹)</td>
<td>143.3</td>
<td>234.8</td>
<td>28.5</td>
</tr>
<tr>
<td>Serum amyloid A (µg ml⁻¹)</td>
<td>153.3</td>
<td>1384.8</td>
<td>67.1</td>
</tr>
</tbody>
</table>
her consciousness and laboratory data improved gradually (Table 1). The results of EEG and brain MRI showed considerable improvements before the patient’s discharge on day 42 of hospital admission. Follow-up examination at 3 months after the initial admission revealed good physical and mental development.

Investigations
We performed a comprehensive examination of pathogen genomes using NGS with MiSeq (Illumina) using the samples of nasal swab, intra-tracheal sputum and blood taken on the day of admission. Briefly, an RNA-seq library was prepared from extracted total RNA using a ScriptSeq...
v2 RNA-Seq Library Preparation kit (Illumina), followed by 150-mer paired-end de novo sequencing with a MiSeq Reagent kit v2 (Illumina); the raw short reads (approx. 1 million reads per sample) were analysed using the MePIC server to characterize potential pathogens, as previously described (Takeuchi et al., 2014). Sequence analysis by NGS suggested that this sample contained HPIV2. Therefore, we confirmed the presence of HPIV2 in the nasal swab using the conventional PCR method with specific primers (Bellau-Pujol et al., 2005). Next, we performed phylogenetic analysis based on the haemagglutinin-neuraminidase (HN) coding region of HPIV2 (305 bp) using Molecular Evolutionary Genetics Analysis (MEGA) software version 5 (Tamura et al., 2011) (Fig. 2). HN glycoprotein is a major antigen in HPIV. In addition, HN glycoprotein might function as a major antigen. In phylogenetic analysis, the reference sequences of the HN coding region were obtained by BLAST. Levels of the anti-HPIV2 antibody elevated 40-fold in the haemagglutination inhibition test after IVIG and methylprednisolone pulse therapy were started; however, they were not detected at the three-month follow-up. No pathogenic viruses, such as EBV, CMV, VZV, HHV6, HHV7 or HSV, were isolated or detected from the patient’s serum (McIver et al., 2005).

**Diagnosis**

Acute encephalopathy related to human parainfluenza virus type 2 infection.

**Treatment**

D-Mannitol at a dose of 0.5 g kg\(^{-1}\) four times per day, 0.12 mg midazolam kg\(^{-1}\) h\(^{-1}\) continuously, 1 g high-dose IVIG kg\(^{-1}\) day\(^{-1}\), 30 mg methylprednisolone pulse therapy kg\(^{-1}\) day\(^{-1}\) for 3 days, 500 U thrombomodulin alfa day\(^{-1}\) and 0.5 mg edaravone kg\(^{-1}\) dose\(^{-1}\) twice a day. They were concomitantly administered, similar to the therapy for influenza-virus-associated encephalopathy.

**Outcome and follow-up**

Full recovery without sequelae.

**Discussion**

We have reported here the case of a two-year-old girl diagnosed with acute severe encephalopathy related to HPIV2 infection.

Recently, several extra-pulmonary symptoms caused by respiratory viruses have been reported (Eisenhut, 2006; Kim & You, 2012; Miyamoto et al., 2013; Abenhaim Halpern et al., 2013). RSV infections affecting other organs have been reported (Miyamoto et al., 2013), with the RSV antigen detected in the CSF, myocardium, liver and peripheral blood. Further, a case of acute encephalopathy associated with human metapneumovirus infection in a Japanese three-year-old girl was reported in 2014, in which the human metapneumovirus was detected using PCR from a throat swab but not from CSF, with elevated levels of inflammatory cytokines in the CSF and blood samples (Niizuma et al., 2014).

HPIVs are negative-strand RNA viruses from the Paramyxoviridae family (Henrickson, 2003) with four types; HPIV2 is a member of the genus Rubulavirus (Henrickson, 2003). These HPIVs typically cause respiratory symptoms ranging from mild upper respiratory tract infections to severe lower respiratory tract illness, including croup syndromes, bronchiolitis, and pneumonia. HPIV2 is an important causative agent of upper and lower respiratory tract infections and febrile illness in children as well as severe lower respiratory tract infection in all age groups (Henrickson, 2003).

Recently, several cases of acute encephalopathy related to HPIV have been reported, especially in Asian countries (Kim & You, 2012; Abenhaim Halpern et al., 2013). In these reports, HPIV was detected from patients’ nasal swabs. In these cases, anti-inflammatory treatment using prednisolone was effective, similar to that in our case. In our case, the HPIV2 gene was detected in the patient’s sputum samples, nasal swabs and blood samples using NGS. However, her anti-HPIV2 antibody levels were not elevated 3 months after admission. The anti-HPIV2 antibody level was 40-fold higher after the immunoglobulin product was used. We considered that the negative antibody was possibly due to the immunosuppressive effect of high-dose corticosteroids and high-dose IVIG.

In Japan, paediatric cases of acute encephalopathy, especially influenza-virus-associated encephalopathy, are very severe and often fatal (Kawada et al., 2003). It is well known that in cases of influenza-virus-associated encephalopathy, viral RNA is rarely detected in the CSF; moreover, viral antigens are not detected in the brain on autopsy (Kawada et al., 2003). Cytokine storm as a systemic immune response is considered to be a cause of influenza-virus-associated encephalopathy, wherein elevated levels of inflammatory cytokines, such as IL-1, IL-6 and TNF, are considered to cause the breakdown of the blood–brain barrier, leading to brain oedema (Kawada et al., 2003). In our patient, the elevated levels of AST, LDH and ferritin suggested a systemic immune response; further, the increased serum amyloid A level strongly suggested an inflammatory cytokine response involving IL-1, IL-6 and TNF (Sztein et al., 1982; Patel et al., 1998).

In conclusion, we have presented a case of severe acute encephalopathy associated with HPIV2. We detected the HPIV2 gene using NGS performed using the patient’s sputum samples, nasal swabs and blood samples; however, CSF samples tested negative for the virus. Acute encephalopathy was diagnosed based on the patient’s symptoms, laboratory data, and findings of brain CT, MRI and EEG. Anti-inflammatory and steroid treatment was effective, and the patient recovered without any sequelae. Our experience suggests that HPIV2 can indirectly cause extra-pulmonary illnesses via systemic inflammation, similar to that in influenza-virus-associated encephalopathy.
Ethical statement
The antigen investigation was approved by the Ethics Committee of the National Hospital Organization Fukuyama Medical Center. The patient’s parents provided written informed consent in accordance with the Helsinki Declaration of the World Medical Association.

Acknowledgements
This study was supported by grants from the Ministry of Health, Labour and Welfare of Japan (H25-Shinko-Ippan-015 and H22-Shinko-Ippan-011).

References